Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Healthcare & Pipeline Overview

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company specializing in the development of radiation sensitizers for cancer treatment. Their focus on enhancing the efficacy of existing radiation therapies positions them within the specialty drug market, addressing unmet needs in oncology with Ropidoxuridine and Doranidazole.

What Is the Investment Thesis for SHPH?

Shuttle Pharmaceuticals presents a high-risk, high-reward investment opportunity for investors with a long-term horizon. The company's value is primarily tied to the successful clinical development and regulatory approval of its lead drug candidates, Ropidoxuridine and Doranidazole. Positive Phase 2 and Phase 3 trial results could serve as major catalysts, driving significant stock appreciation. However, the company faces substantial risks, including clinical trial failures, regulatory hurdles, and the need for additional capital to fund its operations. With a market capitalization of $2.17M and a negative P/E ratio of -0.21, the company's valuation is speculative and dependent on future success.

Based on FMP financials and quantitative analysis

SHPH Key Highlights

Shuttle Pharmaceuticals is a clinical-stage company with no current revenue, making it a speculative investment.

• The company's focus on radiation sensitizers addresses a significant unmet need in cancer treatment.
• Ropidoxuridine and Doranidazole are in clinical development, targeting brain tumors, soft tissue sarcomas, and pancreatic, lung, and liver cancers.
• The company's small size (9 employees) allows for agility but also presents operational challenges.
• The company's beta of 0.59 suggests lower volatility compared to the overall market.

Who Are SHPH's Competitors?

SHPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SHPH's Key Strengths?

Focus on a specific niche within cancer therapy (radiation sensitization).

• Two drug candidates in clinical development.
• Potential to improve outcomes for cancer patients undergoing radiation therapy.
• Experienced management team with expertise in drug development.

What Are SHPH's Weaknesses?

Limited financial resources.

• Small size and limited infrastructure.
• Dependence on the success of Ropidoxuridine and Doranidazole.
• No current revenue stream.

What Could Drive SHPH Stock Higher?

SHPH catalyst: Announcement of Phase 2 clinical trial results for Ropidoxuridine in brain tumors (estimated Q4 2026).

• Initiation of Phase 2 clinical trial for Doranidazole in pancreatic cancer (estimated Q2 2027).
• Progress in securing strategic partnerships with larger pharmaceutical companies.
• Potential for receiving orphan drug designation for Ropidoxuridine or Doranidazole.

What Are the Key Risks for SHPH?

Financial-distress signal — its Altman Z-Score of -9.19 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to secure additional funding to support clinical development.
• Negative results from clinical trials for Ropidoxuridine or Doranidazole.
• Delays in regulatory approval process.
• Competition from other companies developing cancer therapies.
• Dependence on key personnel and management team.

What Are the Growth Opportunities for SHPH?

• Advancement of Ropidoxuridine: Successful completion of clinical trials for Ropidoxuridine in treating brain tumors and soft tissue sarcomas represents a significant growth opportunity. Positive trial results could lead to regulatory approval and commercialization, generating substantial revenue for Shuttle Pharmaceuticals. The timeline for this growth opportunity is dependent on the pace of clinical trials and regulatory review, potentially materializing within the next 3-5 years.
• Development of Doranidazole: Advancing Doranidazole through clinical trials for pancreatic, lung, and liver cancers offers another avenue for growth. These cancers represent major unmet medical needs, and effective radiation sensitizers could significantly improve treatment outcomes. Successful development and commercialization of Doranidazole could contribute significantly to Shuttle Pharmaceuticals' revenue stream, with potential realization in 5-7 years.
• Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of Shuttle Pharmaceuticals' drug candidates. These partnerships could provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its products to market. The timing and impact of strategic partnerships are uncertain but could provide a significant boost to the company's growth prospects.
• Expansion of Pipeline: Expanding the company's pipeline through the discovery and development of new radiation sensitizers could create additional growth opportunities. This would involve investing in research and development to identify novel drug targets and develop new drug candidates. A broader pipeline would reduce the company's reliance on its current lead products and increase its long-term growth potential. This is a longer-term strategy, with potential impact in 5-10 years.
• Orphan Drug Designation: Pursuing orphan drug designation for Ropidoxuridine and Doranidazole could provide regulatory and financial incentives, including market exclusivity and tax credits. Orphan drug designation is granted to drugs that treat rare diseases or conditions, providing a competitive advantage in the market. Obtaining orphan drug designation could accelerate the development and commercialization of these drugs, contributing to the company's growth prospects. The timeline for this opportunity is dependent on regulatory review and approval.

What Threats Does SHPH Face?

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from other cancer therapies.
• Need for additional capital to fund operations.

What Are SHPH's Competitive Advantages?

• Intellectual property protection for their drug candidates.
• Proprietary formulations and delivery methods for radiation sensitizers.
• Clinical data supporting the safety and efficacy of their drugs.
• Expertise in radiation sensitization and cancer biology.

What Does SHPH Do?

Shuttle Pharmaceuticals Holdings, Inc., operating through its subsidiary Shuttle Pharmaceuticals, Inc., is dedicated to discovering, developing, and commercializing innovative drugs designed to sensitize cancers to radiation therapy. Founded in 2012 and headquartered in Rockville, Maryland, the company is focused on improving cancer treatment outcomes by enhancing the effectiveness of radiation, a cornerstone of cancer care. Their lead product candidates include Ropidoxuridine, an oral halogenated pyrimidine in clinical development for treating brain tumors and soft tissue sarcomas, and Doranidazole, an injectable hypoxic cell radiation sensitizer being developed for pancreatic, lung, and liver cancers. Shuttle Pharmaceuticals aims to address the limitations of radiation therapy, which can be less effective in hypoxic (oxygen-deprived) tumor cells. By developing drugs that specifically target and sensitize these cells, the company hopes to improve tumor control and patient survival rates. The company's pipeline reflects a commitment to addressing cancers with high unmet needs and limited treatment options. Shuttle Pharmaceuticals is currently focused on advancing its clinical programs and seeking strategic partnerships to support the development and commercialization of its products.

What Products and Services Does SHPH Offer?

• Develop drugs to sensitize cancers to radiation therapy.
• Focus on improving the effectiveness of radiation treatment for cancer patients.
• Develop Ropidoxuridine, an oral drug for brain tumors and soft tissue sarcomas.
• Develop Doranidazole, an injectable drug for pancreatic, lung, and liver cancers.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Seek regulatory approval for their drugs from the FDA and other regulatory agencies.

How Does SHPH Make Money?

• Develop and commercialize radiation sensitizing drugs.
• Generate revenue through the sale of approved drugs.
• Potentially generate revenue through licensing agreements or partnerships with other pharmaceutical companies.
• Fund research and development through equity financing and potential grants.

What Industry Does SHPH Operate In?

Shuttle Pharmaceuticals operates within the specialty pharmaceutical sector, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Key trends include the development of personalized medicine, targeted therapies, and immunotherapies. Shuttle Pharmaceuticals' focus on radiation sensitizers positions it within a niche market, targeting the limitations of traditional radiation therapy. Competitors include companies developing similar radiation-enhancing drugs or alternative cancer treatment modalities.

Who Are SHPH's Key Customers?

• Cancer patients undergoing radiation therapy.
• Oncologists and radiation oncologists who prescribe cancer treatments.
• Hospitals and cancer centers that administer radiation therapy.

Key Financial Metrics

Return on assets is -91.6%, showing how much profit it generates from its asset base. A current ratio of 0.30 means current liabilities exceed short-term assets, a liquidity point worth watching.

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Valuation Context

Valued at $2.17M, SHPH is classified as a micro-cap stock. Relative to its peer group, SHPH's quantitative score of 26/100 is below the peer average of 56/100.

Company Profile

Shuttle Pharmaceuticals Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Gaithersburg, US. The company is led by CEO Christopher Robert Cooper. SHPH has traded publicly since 2022.

Shuttle Pharmaceuticals Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.19 places it in the distress zone, a signal of elevated financial risk.

SHPH Financials

SHPH Latest News

SHPH Analyst Consensus

SHPH MoonshotScore

What Investors Ask About Shuttle Pharmaceuticals Holdings, Inc. (SHPH) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources